Jaguar Health Faces New Nasdaq Delisting Threat Over Publicly Held Shares After Reverse Split
JAGX is trading near its 52-week low of $6.63 (1.4% above the low) on elevated volume (3.9× avg).
Summary
Jaguar Health received an additional Nasdaq delisting notice due to insufficient publicly held shares following its recent reverse stock split, further jeopardizing its listing status.
Key Events · Corporate Governance and Compliance · JAGX
-
New Nasdaq Delisting Deficiency
On May 1, 2026, Jaguar Health received a notice from Nasdaq for failing to meet the minimum 500,000 publicly held shares requirement (Rule 5550(a)(4)).
-
Impact of Reverse Stock Split
The deficiency is a direct result of the 1-for-35 reverse stock split effected on April 30, 2026, which reduced publicly held shares to approximately 401,226.
-
Additional Basis for Delisting
This new non-compliance serves as an additional basis for delisting, and the Nasdaq Hearings Panel will consider it in their decision regarding the company's continued listing.
-
Ongoing Compliance Challenges
The company remains non-compliant with both the minimum $1 bid price requirement and the publicly held shares requirement, with a deadline of May 8, 2026, to present its views to the Panel.
Analysis · JAGX · Life Sciences
Jaguar Health has received an additional delisting notice from Nasdaq, citing non-compliance with the minimum 500,000 publicly held shares requirement. This new deficiency directly results from the recent 1-for-35 reverse stock split, which reduced the number of publicly held shares to approximately 401,226. This compounds the company's existing struggles, including a prior bid price deficiency and a going concern warning in its latest 10-K. The Nasdaq Hearings Panel will now consider this new issue in its decision regarding the company's continued listing, adding significant pressure as the company navigates severe financial distress and ongoing compliance challenges. The company must present its views to the Panel by May 8, 2026.
At the time of this filing, JAGX was trading at $6.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7M. The 52-week trading range was $6.63 to $462.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.